

Written by David Kopp | September 1, 2026

 An experimental melanoma (skin cancer) treatment shows promising late-stage results. This treatment, pioneered by Merck, a pharmaceutical company, and Moderna, a biotech company, met key goals in a Phase 3 trial involving 1,137 patients at high risk for melanoma returning after surgery. The experimental treatment still awaits federal approval but ignites hope for the over 1,000,000 people living with melanoma worldwide.